ITS
InsiderTrading
TradesInsidersCompaniesCluster BuysRankingsAbout
ITS
InsiderTrading Screener

Track SEC Form 4 insider trades. See what corporate insiders are buying and selling.

Browse

  • Trades
  • Insiders
  • Companies
  • Cluster Buys
  • Rankings

Top Insiders

  • Mark Zuckerberg
  • Elon Musk
  • Jamie Dimon
  • Satya Nadella
  • Lisa Su
  • Jensen Huang

Screeners

  • CEO & CFO Purchases
  • Director Purchases
  • Top Buys This Week
  • Top Sales This Week
  • 10b5-1 Trades
  • Buy/Sell Ratios
  • Politician Overlap
  • Sectors

Learn

  • Learn
  • What is a Form 4?
  • About & Methodology
  • What are Cluster Buys?
  • Top Insider Rankings
  • Contact Us
  • Privacy Policy
  • Terms of Use

Data

  • SEC EDGAR Form 4 ↗
  • CongressStock.com ↗
  • Track13F.com ↗
  • About the data
© 2026 InsiderTradingScreener.com. Data from SEC EDGAR Form 4 filings.For informational purposes only. Not financial advice.
Home/Insiders/Malady Kyle

Malady Kyle

Insider

Insider
Total trades
41
Bought (open market)
$0
Sold (open market)
$4.8M
Tickers traded
2
Malady Kyle, EVP and Group CEO of Verizon Business, has filed 84 Form 4 transactions across two companies, with a clear directional bias toward selling. Over the reporting period, Kyle recorded zero open-market purchases and $4.29 million in total sales, while acquisitions—almost entirely compensation-related grants and option exercises—totaled just $382,235. The most significant activity occurred on February 27, 2026, when Kyle exercised options and had shares withheld for taxes across three separate VZ transactions, with tax-withholding values of $855,238, $854,837, and $832,424. A larger sale on February 11, 2026, saw $2.84 million in shares withheld, marking the single largest dollar event in the filing history. The recent pattern is dominated by recurring "A" codes—grants or awards—in VZ, appearing roughly every two weeks in amounts near $1,738. These are compensation events, not discretionary purchases, and they cluster consistently from January through July 2026. The only non-VZ activity is a single DXCM grant on May 28, 2026, valued at $0, suggesting a board or advisory role with no cash value. Notably, Kyle has no recent open-market buys or sells, meaning the $4.29 million in total sales stems entirely from earlier vesting and tax-withholding mechanics rather than active trading decisions. The absence of any "P" (purchase) codes across 84 filings signals a purely passive accumulation and disposition cycle tied to equity compensation. Kyle’s realized value comes from automatic share sales to cover tax obligations—standard for executives with large restricted stock units—rather than a deliberate market-timing strategy. The consistent biweekly VZ grants indicate a scheduled compensation plan, while the February spike reflects a concentrated vesting event. Taken together, the filings show an insider who is not actively buying or selling on conviction, but rather managing the mechanical consequences of a substantial equity package.

AI-assisted summary

12-month activity

Monthly buy vs sell totals from Malady Kyle's Form 4 filings.

BuysSellsFilings with no price (gifts, grants)
Show data table
MonthBuysSellsFilings
November 2025$0$04
December 2025$0$05
January 2026$0$02
February 2026$0$011
March 2026$0$02
April 2026$0$03
May 2026$0$03
June 2026$0$02
July 2026$0$03
August 2026$0$109K4
September 2026$0$270K7
October 2026$0$146K5

Recent trades

Most recent Form 4 filings by Malady Kyle.

  • Malady Kylegranted134.656 shares ofVZat $12.91$2KOct 22 · filed Oct 23Details
  • Malady Kylesold1,100 shares ofVZat $44.48$49KOct 20 · filed Oct 21Details
  • Malady Kylesold1,100 shares ofVZat $42.93$47KOct 13 · filed Oct 14Details

Explore insider screeners

Latest CEO & CFO PurchasesLatest CEO & CFO SalesDirector PurchasesOfficer PurchasesTop Purchases This WeekTop Sales This WeekTop Officer Buys (Month)10% Owner Filings10b5-1 Planned TradesDiscretionary TradesBuy/Sell RatiosPolitician-Insider Overlap
  • Malady Kylegranted131.364 shares ofVZat $13.23$2KOct 8 · filed Oct 9Details
  • Malady Kylesold1,100 shares ofVZat $45.75$50KOct 6 · filed Oct 7Details
  • Malady Kylesold1,100 shares ofVZat $46.4$51KSep 29 · filed Sep 30Details
  • Malady Kylegranted128.695 shares ofVZat $13.51$2KSep 24 · filed Sep 28Details
  • Malady Kylesold1,100 shares ofVZat $47.65$52KSep 22 · filed Sep 23Details
  • Malady Kylesold1,100 shares ofVZat $51.19$56KSep 15 · filed Sep 16Details
  • Malady Kylegranted121.911 shares ofVZat $14.26$2KSep 10 · filed Sep 11Details
  • Malady Kylesold1,100 shares ofVZat $49.98$55KSep 8 · filed Sep 9Details
  • Malady Kylesold1,100 shares ofVZat $50.5$56KSep 1 · filed Sep 2Details
  • Malady Kylegranted123.236 shares ofVZat $14.11$2KAug 27 · filed Aug 31Details
  • Malady Kylesold1,100 shares ofVZat $50.06$55KAug 25 · filed Aug 26Details
  • Malady Kylesold1,100 shares ofVZat $48.68$54KAug 18 · filed Aug 19Details
  • Malady Kylegranted126.31 shares ofVZat $13.76$2KAug 13 · filed Aug 14Details
  • Malady Kylegranted132.072 shares ofVZat $13.16$2KJul 30 · filed Aug 3Details
  • Malady Kylegranted138.74 shares ofVZat $12.53$2KJul 16 · filed Jul 17Details
  • Malady Kylegranted144.943 shares ofVZat $11.99$2KJul 1 · filed Jul 6Details
  • Malady Kylegranted132.86 shares ofVZat $13.08$2KJun 17 · filed Jun 18Details
  • View all 41 trades →